)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shattuck Labs
Shattuck Labs (STTK) investor relations material
Shattuck Labs Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary5 Nov, 2026
Overview and pipeline
Developing potentially first-in-class DR3-blocking monoclonal and bispecific antibodies for inflammatory and immune-mediated diseases.
SL-325 is the lead program; RECEPTIVE-CD1 Phase 2b in Crohn’s disease is ongoing, and RECEPTIVE-HS1 Phase 2b in hidradenitis suppurativa was expected to start in 4Q 2026.
SL-846 is a half-life-extended DR3 × IL-23 receptor bispecific; SL-425 is a half-life-extended DR3 antibody, with additional preclinical bispecifics in development.
DR3-targeting rationale
DR3 is described as constitutively expressed in inflamed and adjacent tissue, while TL1A expression is transient; receptor blockade may provide more complete, durable inhibition of the TL1A/DR3 pathway.
Targeting DR3 rather than soluble TL1A is designed to avoid circulating immune-complex formation; SL-325’s 3.7% Phase 1 ADA rate compares with reported 48–82% rates for anti-TL1A antibodies in similar Phase 1 trials.
Durable inhibition of TL1A binding to DR3 may support quarterly maintenance dosing and a subcutaneous autoinjector-compatible format.
SL-325 phase 1 results
The completed healthy-participant Phase 1 included 72 participants across single- and multiple-ascending-dose cohorts, with doses from 0.1 to 30 mg/kg.
SL-325 was reported as well tolerated across dose levels; no severe or serious adverse events were reported, and one participant discontinued after a mild Grade 1 infusion reaction.
No changes in measured serum cytokines, TL1A concentrations, or assessed immune-cell proportions indicated residual DR3 agonism.
PK increased dose-proportionally from 0.1 to 30 mg/kg; estimated half-life was 16 days, with a repeated-dose accumulation ratio of 1.64–1.75.
A single dose achieved full DR3 occupancy at 0.1 mg/kg; blockade lasted months at doses ≥1 mg/kg, potentially enabling quarterly maintenance dosing.
ADA were detected in 2/54 SL-325-treated participants (3.7%); titers remained low, with no reported impact on PK or receptor occupancy.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shattuck Labs
- SL-325 Phase 2b trials advance; $196.3M in liquidity supports operations into 2029.STTK
Q3 2026 - SL-325 demonstrates low immunogenicity and durable efficacy, with pivotal trials underway.STTKCorporate presentation
- DR3-targeted therapies show durable efficacy and low immunogenicity, with broad expansion plans.STTK12th Annual Cantor Fitzgerald Global Healthcare Conference
- DR3 blockade targets durable, low-immunogenicity IBD therapy with pivotal data expected in 2028.STTKWells Fargo 21st Annual Healthcare Conference
- SL-325, a first-in-class DR3 antagonist for IBD, shows superior preclinical efficacy and durability.STTKCorporate presentation
- SL-325, a first-in-class DR3 antagonist for IBD, shows superior preclinical efficacy and safety.STTKCorporate presentation
- SL-325 offers a first-in-class DR3 blockade with durable efficacy and low immunogenicity for IBD.STTKCorporate presentation
- SL-325 completed Phase 1 with strong safety; $208.3M cash funds operations into 2029.STTKQ2 2026
- Lead DR3 antibody SL-325 shows promise for IBD with strong safety and low immunogenicity.STTKCorporate presentation
Next Shattuck Labs earnings date
Q4 20269 Mar, 2027
Shattuck Labs
Next Shattuck Labs earnings date
Q4 20269 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Shattuck Labs Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create biologic therapies that enhance the body's immune response. Shattuck Labs' technology is designed to modulate immune pathways, potentially improving outcomes for patients with challenging conditions. The company is involved in research and development efforts, advancing its immunotherapy candidates through clinical trials. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.